人福醫藥(600079.SH):宜昌人福右美託咪定透皮貼劑獲批臨牀試驗
格隆匯3月10日丨人福醫藥(600079.SH)公佈,公司控股子公司宜昌人福藥業有限責任公司(簡稱“宜昌人福”,公司持有其80%的股權)近日收到國家藥品監督管理局核准簽發的右美託咪定透皮貼劑(II)的《藥物臨牀試驗批准通知書》。
右美託咪定透皮貼劑(II)是宜昌人福開發的一款改善圍術期患者睡眠質量的透皮貼劑品種,目前國內尚無同類型產品上市,已上市產品為常規劑型鹽酸右美託咪定注射液。根據米內網數據顯示,2020年鹽酸右美託咪定注射劑在我國城市、縣級及鄉鎮三大終端公立醫院的銷售額約為人民幣40億元,主要生產廠商為揚子江藥業集團有限公司等。截至目前,宜昌人福該項目累計研發投入約為人民幣900萬元。
根據我國藥品註冊相關的法律法規要求,宜昌人福在收到上述藥物臨牀試驗批准通知書後,將着手啟動藥物的臨牀研究相關工作,待完成臨牀研究後,將向國家藥品監督管理局遞交臨牀試驗數據及相關資料,申報生產上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.